Firazyr
(Icatibant)ApprovedSmall molecule
TakedaFirazyr is a small molecule that works as a Bradykinin B2 Receptor Antagonist.[2] It is being used across 7 indications, with its most advanced program in Approved.[1]
Firazyr is one of 150 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Approved.
7
Indications
19
Total Trials
2
Active Trials
149
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hereditary Angioedema5 trials
COVID-193 trials
Angioedema3 trials
Tics1 trial
6 more indications
Hereditary Angioedema (HAE)1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Aug 25, 2011
FIRAZYR
NDA NDA022150
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icatibant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]